Abstract
Systemic fungal infections of humans and economically important animals are increasingly common throughout the world. These infections are severe and often hard to treat with existing safe, oral medications. Thus there has been increasing research on alternatives resulting in study of natural and synthetic inhibitors of 1,3-β-Glucan synthase (GS) and chitin synthase (CS)-enzymes important in the biosynthesis of fungal cell walls that are not utilized in human biochemistry. Some such agents have recently been introduced into parenteral clinical use. There is hope that safe agents of this type with oral activity may yet emerge. This active area of research and its historic context with alternative agents is reviewed herein.
Keywords: Antifungal drugs, amphotericin B, conazoles, flucytosine, morpholine, 1, 3-β-glucan synthase inhibitors, echinocandins, triterpene glycosides, kramerixin, chitin synthase inhibitors.
Current Medicinal Chemistry
Title:Recent Progress in the Chemotherapy of Human Fungal Diseases. Emphasis on 1,3-β-Glucan Synthase and Chitin Synthase Inhibitors
Volume: 20 Issue: 38
Author(s): Anwer Basha, Fatima Basha, Syed Kashif Ali, Paul R. Hanson, Lester A. Mitscher and Berl R. Oakley
Affiliation:
Keywords: Antifungal drugs, amphotericin B, conazoles, flucytosine, morpholine, 1, 3-β-glucan synthase inhibitors, echinocandins, triterpene glycosides, kramerixin, chitin synthase inhibitors.
Abstract: Systemic fungal infections of humans and economically important animals are increasingly common throughout the world. These infections are severe and often hard to treat with existing safe, oral medications. Thus there has been increasing research on alternatives resulting in study of natural and synthetic inhibitors of 1,3-β-Glucan synthase (GS) and chitin synthase (CS)-enzymes important in the biosynthesis of fungal cell walls that are not utilized in human biochemistry. Some such agents have recently been introduced into parenteral clinical use. There is hope that safe agents of this type with oral activity may yet emerge. This active area of research and its historic context with alternative agents is reviewed herein.
Export Options
About this article
Cite this article as:
Basha Anwer, Basha Fatima, Ali Kashif Syed, Hanson R. Paul, Mitscher A. Lester and Oakley R. Berl, Recent Progress in the Chemotherapy of Human Fungal Diseases. Emphasis on 1,3-β-Glucan Synthase and Chitin Synthase Inhibitors, Current Medicinal Chemistry 2013; 20 (38) . https://dx.doi.org/10.2174/092986732038131128102220
DOI https://dx.doi.org/10.2174/092986732038131128102220 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells
Current Cancer Drug Targets Using Nutrigenomics to Evaluate Apoptosis as a Preemptive Target in Cancer Prevention
Current Cancer Drug Targets Targeted Anti-leukemic Therapy as Disease-stabilizing Treatment for Acute Myeloid Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will it be Possible to Combine these Strategies with Retransplantation or Donor Lymphocyte Infusions?
Current Cancer Drug Targets Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective
Current Pharmaceutical Biotechnology New Drugs for Follicular Lymphoma in Older Adults
Anti-Cancer Agents in Medicinal Chemistry Differential Impacts of Azole Antifungal Drugs on the Pharmacokinetic Profiles of Dasatinib in Rats by LC-MS-MS
Current Drug Metabolism Telomerase as a Cancer Target. Development of New Molecules
Current Topics in Medicinal Chemistry Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Adenovirus Mediated Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Gene Therapy for Resectable Malignant Glioma
Current Gene Therapy New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Invasive Fungal Infection in Febrile Patients with Hematologic Malignancies Undergoing Chemotherapy in Iran
Endocrine, Metabolic & Immune Disorders - Drug Targets Apoptosis Signaling Pathways in Anticancer Therapy
Current Cancer Therapy Reviews MicroRNAs and the Warburg Effect: New Players in an Old Arena
Current Gene Therapy NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates
Anti-Cancer Agents in Medicinal Chemistry Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy
Cardiovascular & Hematological Agents in Medicinal Chemistry New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors
Current Cancer Drug Targets Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry